These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 38088937)
1. The clinical effectiveness of mepolizumab treatment in severe eosinophilic asthma; outcomes from four years cohort evaluation. Reilly C; Raja A; Anilkumar P; Sullivan J; White L; Bahron A; Marsh J; Mansur AH J Asthma; 2024 Jun; 61(6):561-573. PubMed ID: 38088937 [TBL] [Abstract][Full Text] [Related]
2. Impact of mepolizumab on exacerbations in severe asthma: Results from a U.S. insurance claims data base. Ortega H; Hahn B; Bogart M; Bell CF; Bancroft T; Chastek B; Llanos JP Allergy Asthma Proc; 2020 Sep; 41(5):341-347. PubMed ID: 32867888 [No Abstract] [Full Text] [Related]
3. A real-life cohort of mepolizumab treatment in severe eosinophilic asthma. Laorden D; Hernández I; Domínguez-Ortega J; Romero D; Álvarez-Sala R; Quirce S Eur Ann Allergy Clin Immunol; 2024 Jul; 56(4):169-175. PubMed ID: 36927725 [No Abstract] [Full Text] [Related]
4. REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study. Domingo Ribas C; Carrillo Díaz T; Blanco Aparicio M; Martínez Moragón E; Banas Conejero D; Sánchez Herrero MG; Drugs; 2021 Oct; 81(15):1763-1774. PubMed ID: 34586602 [TBL] [Abstract][Full Text] [Related]
5. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. Chapman KR; Albers FC; Chipps B; Muñoz X; Devouassoux G; Bergna M; Galkin D; Azmi J; Mouneimne D; Price RG; Liu MC Allergy; 2019 Sep; 74(9):1716-1726. PubMed ID: 31049972 [TBL] [Abstract][Full Text] [Related]
6. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study. McDowell PJ; Diver S; Yang F; Borg C; Busby J; Brown V; Shrimanker R; Cox C; Brightling CE; Chaudhuri R; Pavord ID; Heaney LG; Lancet Respir Med; 2021 Oct; 9(10):1174-1184. PubMed ID: 33971168 [TBL] [Abstract][Full Text] [Related]
7. Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Bermejo I; Stevenson M; Cooper K; Harnan S; Hamilton J; Clowes M; Carroll C; Harrison T; Saha S Pharmacoeconomics; 2018 Feb; 36(2):131-144. PubMed ID: 28933002 [TBL] [Abstract][Full Text] [Related]
8. Real-World Effectiveness and the Characteristics of a "Super-Responder" to Mepolizumab in Severe Eosinophilic Asthma. Kavanagh JE; d'Ancona G; Elstad M; Green L; Fernandes M; Thomson L; Roxas C; Dhariwal J; Nanzer AM; Kent BD; Jackson DJ Chest; 2020 Aug; 158(2):491-500. PubMed ID: 32275980 [TBL] [Abstract][Full Text] [Related]
9. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma. Pertzov B; Unterman A; Shtraichman O; Shitenberg D; Rosengarten D; Kramer MR J Asthma; 2021 Jan; 58(1):79-84. PubMed ID: 31479312 [TBL] [Abstract][Full Text] [Related]
11. Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis. Kallieri M; Zervas E; Katsoulis K; Fouka E; Porpodis K; Samitas K; Papaioannou AI; Kipourou M; Gaki E; Vittorakis S; Markatos M; Dimakou K; Ampelioti S; Koukidou S; Makris M; Ntakoula M; Mitrova MH; Glynos K; Antoniou KM; Gaga M; Tzanakis N; Markopoulou K; Papakosta D; Bakakos P; Loukides S Int Arch Allergy Immunol; 2020; 181(8):613-617. PubMed ID: 32570256 [TBL] [Abstract][Full Text] [Related]
13. Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety. van Toor JJ; van der Mark SC; Kappen JH; In 't Veen JCCM; Braunstahl GJ J Asthma; 2021 May; 58(5):651-658. PubMed ID: 31999203 [No Abstract] [Full Text] [Related]
14. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. Magnan A; Bourdin A; Prazma CM; Albers FC; Price RG; Yancey SW; Ortega H Allergy; 2016 Sep; 71(9):1335-44. PubMed ID: 27087007 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis. Numata T; Nakayama K; Utsumi H; Kobayashi K; Yanagisawa H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K BMC Pulm Med; 2019 Oct; 19(1):176. PubMed ID: 31606052 [TBL] [Abstract][Full Text] [Related]
16. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics. Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856 [TBL] [Abstract][Full Text] [Related]
17. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. Khatri S; Moore W; Gibson PG; Leigh R; Bourdin A; Maspero J; Barros M; Buhl R; Howarth P; Albers FC; Bradford ES; Gilson M; Price RG; Yancey SW; Ortega H J Allergy Clin Immunol; 2019 May; 143(5):1742-1751.e7. PubMed ID: 30359681 [TBL] [Abstract][Full Text] [Related]